Literature DB >> 27246286

Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer.

Miroslava Juríková1, Ľudovít Danihel2, Štefan Polák3, Ivan Varga3.   

Abstract

The proliferative activity of tumour cells represents an important prognostic marker in the diagnosis of cancer. One of the methods for assessing the proliferative activity of cells is the immunohistochemical detection of cell cycle-specific antigens. For example, Ki67, proliferating cell nuclear antigen (PCNA), and minichromosome maintenance (MCM) proteins are standard markers of proliferation that are commonly used to assess the growth fraction of a cell population. The function of Ki67, the widely used marker of proliferation, still remains unclear. In contrast, PCNA and MCM proteins have been identified as important participants of DNA replication. All three proteins only manifest their expression during the cell division of normal and neoplastic cells. Since the expression of these proliferative markers was confirmed in several malignant tumours, their prognostic and predictive values have been evaluated to determine their significance in the diagnosis of cancer. This review offers insight into the discovery of the abovementioned proteins, as well as their current molecular and biological importance. In addition, the functions and properties of all three proteins and their use as markers of proliferation in the diagnosis of breast cancer are described. This work also reveals new findings about the role of Ki67 during the mitotic phase of the cell cycle. Finally, information is provided about the advantages and disadvantages of using all three antigens in the diagnosis of cancer.
Copyright © 2016 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Breast cancer; Diagnosis; Ki67; MCM; PCNA; Prognosis; Proliferative markers

Mesh:

Substances:

Year:  2016        PMID: 27246286     DOI: 10.1016/j.acthis.2016.05.002

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  152 in total

1.  FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells.

Authors:  Ming-Min Chang; Meng-Shao Lai; Siou-Ying Hong; Bo-Syong Pan; Hsin Huang; Shang-Hsun Yang; Chia-Ching Wu; H Sunny Sun; Jih-Ing Chuang; Chia-Yih Wang; Bu-Miin Huang
Journal:  Cancer Sci       Date:  2018-10-23       Impact factor: 6.716

2.  The Novel Transcription Factor CREB3L4 Contributes to the Progression of Human Breast Carcinoma.

Authors:  Qian Pu; Li Lu; Ke Dong; Wen-Wen Geng; Yan-Rong Lv; Hai-Dong Gao
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-02-06       Impact factor: 2.673

3.  [Screening and verification of key genes in T-cell acute lymphoblastic leukemia].

Authors:  Guang-Jie Jiang; Yan-Hua Chen; Wei Guo; Hang Zhang; Lin Zou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-03-20

4.  MiR-34b-5p inhibits cell proliferation, migration and invasion through targeting ARHGAP1 in breast cancer.

Authors:  Lifeng Dong; Fangfang Chen; Yangfan Fan; Jingpei Long
Journal:  Am J Transl Res       Date:  2020-01-15       Impact factor: 4.060

5.  Phosphorylation of proliferating cell nuclear antigen promotes cancer progression by activating the ATM/Akt/GSK3β/Snail signaling pathway.

Authors:  Bo Peng; Janice Ortega; Liya Gu; Zhijie Chang; Guo-Min Li
Journal:  J Biol Chem       Date:  2019-03-11       Impact factor: 5.157

6.  Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells.

Authors:  Caroline Theresa Seebauer; Stefan Brunner; Gabriel Glockzin; Pompiliu Piso; Petra Ruemmele; Hans-Juergen Schlitt; Edward Kenneth Geissler; Stefan Fichtner-Feigl; Rebecca Kesselring
Journal:  Oncoimmunology       Date:  2016-10-14       Impact factor: 8.110

7.  Inter-Individual Variation in Response to Estrogen in Human Breast Explants.

Authors:  Karen A Dunphy; Amye L Black; Amy L Roberts; Aman Sharma; Zida Li; Sneha Suresh; Eva P Browne; Kathleen F Arcaro; Jennifer Ser-Dolansky; Carol Bigelow; Melissa A Troester; Sallie S Schneider; Grace Makari-Judson; Giovanna M Crisi; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-03-09       Impact factor: 2.673

8.  Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.

Authors:  Adrián Blanco-Gómez; Lourdes Hontecillas-Prieto; Roberto Corchado-Cobos; Natalia García-Sancha; Jesús Pérez-Losada; Sonia Castillo-Lluva; Nélida Salvador; Andrés Castellanos-Martín; María Del Mar Sáez-Freire; Marina Mendiburu-Eliçabe; Diego Alonso-López; Javier De Las Rivas; Mar Lorente; Ana García-Casas; Sofía Del Carmen; María Del Mar Abad-Hernández; Juan Jesús Cruz-Hernández; César Augusto Rodríguez-Sánchez; Juncal Claros-Ampuero; Begoña García-Cenador; Javier García-Criado; Akira Orimo; Thomas Gridley
Journal:  Cancer Res       Date:  2020-10-06       Impact factor: 12.701

9.  Exploring cisplatin resistance in ovarian cancer through integrated bioinformatics approach and overcoming chemoresistance with sanguinarine.

Authors:  Lihua Yang; Hongbo Zhao; Xueqin Yin; Hong Liang; Zhi Zheng; Qiang Shen; Wanqin Hu
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

10.  miR-144 suppresses proliferation and induces apoptosis of osteosarcoma cells via direct regulation of mTOR expression.

Authors:  Yuan-Fei Ren; Tie-Hui Zhang; Sheng Zhong; Yan-Tao Zhao; Ya-Nan Lv
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.